Stereotaxis, Inc. (STXS)
| Market Cap | 496.34M |
| Revenue (ttm) | 26.63M |
| Net Income (ttm) | -8.02M |
| Shares Out | 72.75M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $6.70 |
| Previous Close | $6.41 |
| Change ($) | 0.29 |
| Change (%) | 4.52% |
| Day's Open | 6.42 |
| Day's Range | 6.42 - 6.72 |
| Day's Volume | 255,422 |
| 52-Week Range | 3.03 - 8.62 |
ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will releas...
ST. LOUIS, April 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chair...
ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medic...
Robotics stocks should have years of growth ahead as the trend toward automation continues. These 5 names aren't cheap, but look worth paying up for.
Stereotaxis Inc. (STXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0.00% and 15.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...
ST. LOUIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO perfor...
ST. LOUIS, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, ...
ST. LOUIS, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript
Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript
ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...
ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...
ST. LOUIS, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has complete...
ST. LOUIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisc...
ST. LOUIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisch...
ST. LOUIS, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pioneering pub...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2020 Results - Earnings Call Transcript
ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results...
ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote...
ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will rel...
ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in...
ST. LOUIS, June 22, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the company...
ST. LOUIS, June 18, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisch...
ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a...
ST. LOUIS, May 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2020 Results - Earnings Call Transcript
Stereotaxis, Inc. (STXS) CEO David Fischel on Q4 2019 Results - Earnings Call Transcript
ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U...
Stereotaxis: A Small But Stellar Performer In The Medical Robotics Space
Stereotaxis: Poised For A Strong 2020
ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest...
A series of financial missteps led to a delisting for Stereotaxis in 2013. Now that a new CEO has made some progress toward a turnaround, the robotic technology company may deserve a second chance.
Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2019 Results - Earnings Call Transcript
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the...
ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration...
ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with th...
ST. LOUIS, Mo., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced t...
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Ody... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Aug 12, 2004 |
| CEO David Fischel | Employees 120 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol STXS |
Financial Performance
In 2020, Stereotaxis's revenue was $26.63 million, a decrease of -7.86% compared to the previous year's $28.90 million. Losses were -$6.65 million, 44.8% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for Stereotaxis stock is "Strong Buy." The 12-month stock price forecast is 9.33, which is an increase of 39.25% from the latest price.